The fund plans to create a portfolio of 20-25 companies addressing gaps in the market for both services and products

The IXP Lifesciences Catalyst Fund has targeted a corpus of Rs 200 crore with a greenhouse option of Rs 100 crore, as per a press release. The fund plans to create a portfolio of 20-25 companies addressing gaps in the market for both services and products.

Ketki Tulpule, Chief Innovation Officer (CIO), IXP said, “Biotech requires investors with scientific expertise, industry knowledge, and operational experience to succeed. We are glad to have onboarded industry veterans as council members and advisors who add to the scientific heft of the fund”.

The fund will be utilised to invest across innovation in areas such as pharma, biotechnology, medical technology, speciality chemicals, agrotechnology and nutraceuticals.

Vishal Goel, Partner at IXP, Co-founder, JV Ventures commented, “The Indian Lifesciences industry is dynamic with large untapped potential. Through IXP Venture Studio, we will co-create companies along with scientists for ideas addressing unmet needs in the market. Unlike traditional VCs, IXP has a hands-on approach through active participation from concept to scale. The Ventureprenuer Program has been designed to transform scientists into founders”.